Higher dose Wegovy demonstrates nearly 28% weight loss

Danish pharma major Novo Nordisk (NOV: N) presented a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) taking place in Istanbul, Turkey, showing that the higher dose of the weight loss drug Wegovy (semaglutide) Is highly effective at helping people with obesity lose significant amounts of weight regardless of how quickly their body responds to the treatment.

Moreover, a separate STEP UP sub-analysis presented at ECO shows that most of the weight loss with Wegovy was coming from body fat, and most of the muscle mass was kept. The STEP UP trial in people with obesity tested the higher dose of semaglutide (7.2mg) against the 2.4mg dose and placebo over 72 weeks in over 1,400 adults living with obesity without type 2 diabetes.